The effect of dehydroepiandrosterone supplementation for patients with diminished ovarian reserve undergoing in vitro fertilization.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005002

Enrollment

Unknown

Registered

2014-07-23

Start date

2013-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve

Interventions

DHEA group:DHEA 75 mg daily for three months

DHEA+Climen group:DHEA 75mg+climen 1mg daily for three months

control group:Placebo

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1) an elevated day 3 FSH level more than 10 mIU/mL or FSH/LH more than 3; 2) the number of antral follicle count less than five; 3) a previous poor ovarian response: retrieval of fewer than five oocytes or cycle cancellation due to poor response to ovarian stimulation. A diagnosed with DOR was reached if they fulfill any of the above three features.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had any of the following: 1) a history of ovarian cystectomy or oophorectomy; 2) a diagnosis of endometriosis; 3) a history of DHEA supplementation or hormonal replacement therapy.

Design outcomes

Primary

Measure	Time frame
Bmp-15;GDF-9;AMH;	—

Countries

China

Contacts

Public ContactZhaolian Wei

weizhaolian_1@126.com+86 13865916162

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 7, 2026